#renal cell carcinoma

Three-Drug Combination Slows Progression of Advanced Kidney Cancer

Patients previously treated with immune checkpoint inhibitors and anti-angiogenics showed improved progression free survival.

An AI–based tool can evaluate photos of kidney tumor samples and may help predict treatment responses, report Dana-Farber researchers.

Other studies focused on bladder cancer, prostate cancer and liquid biopsies.

Researchers applied single-nucleus RNA sequencing and spatial transcriptomics to identify potential therapeutic targets.

Chase Griffith, 46, lives in Dallas with his wife and two sons. He has metastatic chromophobe renal cell carcinoma.

A unique analysis measures treatment-free survival after immunotherapy in patients with advanced renal cell carcinoma.

A new study sheds light on how cholesterol fills clear-cell renal cell carcinoma with cholesterol.

Targeted therapy and immunotherapy combination doubles response rate for people with advanced renal cell carcinoma.

In patients at high risk of relapse, adjuvant therapy with Keytruda prolonged disease-free survival.

The kinase inhibitor delayed disease progression by 27% for people who had tried at least two prior therapies.

Opdivo plus Cabometyx reduced the risk of death by 40%.

First-line Lenvima plus Keytruda yields better overall survival for patients with metastatic kidney cancer.

The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.